|

Long-term Safety and Effectiveness of Growth Hormone With GHD, TS, CRF, SGA , ISS and PWS in Children

RECRUITINGSponsored by LG Chem
Actively Recruiting
SponsorLG Chem
Started2012-01
Est. completion2032-12-31
Eligibility
Age2 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT01604395

Summary

The purpose of this study is to evaluate the long-term safety and effectiveness of growth hormone (Eutropin Inj./Eutropin plus Inj.) treatment with GHD (Growth Hormone Deficiency), TS (Turner Syndrome),CRF (Chronic Renal Failure), SGA (Small for Gestational Age), and ISS (Idiopathic Short Stature).

Eligibility

Age: 2 Years+Healthy volunteers accepted
Inclusion Criteria:

* short stature children aged 2 years or more
* children with GHD,TS, CRF, SGA or ISS
* written informed consent from the person, person's parent or legal guardian

Conditions6

Chronic Renal FailureGrowth Hormone DeficiencyHeart DiseaseIdiopathic Short StatureSmall for Gestational AgeTurner Syndrome

Browse More Trials

Heart Disease trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.